贲门癌组织诱骗受体3表达及其临床意义的探讨

Expression of deceptive receptor-3 in tissue of cardiac cancer and its clinical significance

目的:探讨诱骗受体3(DCR3/TR6)在贲门癌组织中表达及其临床病理意义。方法:采用二步法免疫组化技术(Envision)检测66例贲门癌组织中DCR3/TR6的表达情况,分析DCR3/TR6与各临床病理因素的关系。结果:贲门癌组织DCR3/TR6阳性表达率为54.5%(36/66),癌旁正常胃黏膜无DCR3/TR6表达,两者之间差异有统计学意义,P=0.000。DCR3/TR6蛋白在低分化贲门癌中表达为69.0%(29/42),与高、中分化癌的29.2%(7/24)相比,差异有统计学意义,χ2=8.255,P=0.004。在伴有淋巴结转移者表达为68.9%(31/45),无淋巴结转移者表达为23.8%(5/21),差异有统计学意义,χ2=9.988,P=0.002。伴有浆膜层浸润者表达为69.2%(27/39),无浆膜层浸润者表达为33.3%(9/27),差异有统计学意义,χ2=6.908,P=0.009。TNM分期Ⅲ期的贲门癌DCR3/TR6阳性表达率90%(18/20)显著高于Ⅰ、Ⅱ期的39.1%(18/46),χ2=12.569,P=0.000。DCR3/TR6基因表达与贲门癌组织的分化程度、临床分期及淋巴结转移呈正相关,而与贲门癌的年龄、性别及肿瘤大小无相关性。结论:通过阻断凋亡,DCR3/TR6可能促进贲门癌细胞生长,检测DCR3/TR6蛋白表达对于判断贲门癌的恶性程度及病情进展有一定的价值。

OBJECTIVE： To explore the the expression of decep tive receptor-3（DCR3/TR6）in the tissue of cardiac cancer and its clin ical significance. METHODS： Two-step immunohistochemistry technology was adopted to detect the expression of deceptive receptor-3 （DCR3/TR6）in the tissue of cardiac cancer and the relation of the expression to clinicopathologieal features of cardiac cancer was analysed. RESULTS：The positive expression rate of DCR3/TR6 in cardiac canc er tissue was 54.5%（36/66）, meanwhile the expression was not found in normal gastric mucosa, suggesting a significant difference between both, P = 0. 000. Compared with the DCR3/TR6 protein positive expression rate of 29.2 %（7/24） in moderate and high differentiated cardiac cancer tissue, the DCR3/TR6 protein positive expression rate of of 69.0% in low differentiated cardiac cancer tissue （29/42） presented statistical significance,χ^2=8. 255,P=0. 004. The DCR3/TR6 positive expression rate was 68. 9%（31/45） in the pa tients with lymph nodes metastasis, significantly higher than that of 23.8%（5/21） in the patients without lymph nodes metastasis, ;（χ^2=9. 988,P=0. 002. In the meantime, The DCR3/TR6 positive expres sion rate of 69.2%, （27/39） in the patients with serosal infiltration was also significantly higher than that of 33.3% （9/27） in the patients without serosal infiltration, χ^2=6. 908, P = 0. 009. The DCR3/TR6 protein positive expression rate in TNM classification stage Ⅲ cardinc cancer tissue was 90.0G （18/20）, significantly higher than that of 39. 1%（18/46） in stage Ⅰ and stage Ⅱ cardiac cacer, χ^2=12.569,P= 0.000. The DCR3/TR6 gene expression was positively related to the tumor differentiation, clinical stages and lymph nodes metastasis, but not to the age, sex and tumor size. CONCLUSIONS： Through blockade of FasL, DCR3/TR6 may promote tumor growth of cardiac cancer. The detection of DCR3/TR6 protein expression can be worthwhile to judge the malignance and progression of cardiac cancer.